The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The influence of institutional head and neck cancer (HNC) clinical trial accrual on overall survival (OS): An analysis of RTOG 0129.
Evan John Wuthrick
No relevant relationships to disclose
Qiang Zhang
No relevant relationships to disclose
Mitchell Machtay
No relevant relationships to disclose
K. Kian Ang
Consultant or Advisory Role - Bristol-Myers Squibb
David Ira Rosenthal
No relevant relationships to disclose
Felix Nguyen-Tan
No relevant relationships to disclose
Andre Fortin
No relevant relationships to disclose
Craig I. Silverman
No relevant relationships to disclose
Adam Raben
Employment or Leadership Position - NCI HN Committee for Clinical Trials
Harold Kim
No relevant relationships to disclose
Eric M. Horwitz
No relevant relationships to disclose
Nancy E Read
No relevant relationships to disclose
Jonathan Harris
No relevant relationships to disclose
Qian Wu
No relevant relationships to disclose
Maura L. Gillison
No relevant relationships to disclose